Management of anticoagulated patients in implant therapy: a clinical comparative study

Abstract

Anticoagulation therapy should be continued in patients undergoing implant surgery and bone grafting procedures avoiding thromboembolic complications. Surgeons should always apply the most minimally invasive approach to reduce postoperative risks and be able to apply local hemostatic measures in terms of a bleeding complication.

World workshop on oral medicine VII: Direct anticoagulant agents management for invasive oral procedures: A systematic review and meta‐analysis

“…However, one case of excessive bleeding was observed during and after surgery in the same patient, an 84‐year‐old diabetic man, who was treated in an operating room for multiple teeth extractions (18 teeth) and contemporary facial abscess drainage (Breik et al., ). The intra‐operative bleeding events were classified in one study involving implant surgeries as low (3/16), moderate (11/16), and severe (2/16; Clemm et al., ). Another study recorded minor intra‐operative bleeding during an incisional biopsy, controlled by suturing (Hassona et al., ).…”

“…Of the six studies, one study was assessed as good quality, four were evaluated as fair quality, and one of poor quality (Table ). Risk of bias of the 21 studies was assessed using the Newcastle‐Ottawa scale: two studies received a low risk of bias score (seven stars, Miller & Miller, ; Zeevi et al., ), 16 studies received a high risk of bias score (six stars, Andrade et al., ; Berton et al., ; Caliskan et al., ; Clemm et al., ; Gómez‐Moreno et al., , ; Hanken et al., ; Kwak et al., ; Lababidi et al., ; Mauprivez et al., ; Miclotte et al., ; Miranda et al., ; Morimoto et al., ; Patel et al., ; Yagyuu et al., and five stars, Johnston, ), and three case‐series received a very high risk of bias score (one star, Abayon et al., ; Breik et al., ; Hassona et al., ; Table ).…”

“…None of the included studies was a randomized controlled trial (RCT). Nine articles were prospective case-control studies (Andrade et al, 2018;Berton et al, 2018;Caliskan, Tükel, Benlidayi, & Deniz, 2017;Clemm et al, 2016;Gómez-Moreno et al, 2016Mauprivez et al, 2016;Miclotte et al, 2017;Miranda et al, 2016), four were retrospective case-control studies (Hanken et al, 2016;Kwak et al, 2018;Lababidi et al, 2018;Yagyuu et al, 2017), and five studies were retrospective (Johnston, 2015;Miller & Miller, 2018;Morimoto, Yokoe, Imai, Sugihara, & Futatsuki, 2016;Zeevi et al, 2017) and prospective (Patel et al, 2017) observational studies, reporting data from medical records. Three studies were case-series (Abayon, Kolokythas, Siu, & Elad, 2016;Breik, Cheng, Sambrook, & Goss, 2014;Hassona, Malamos, Shaqman, Baqain, & Scully, 2018).…”

Dental Implants in the Medically Compromised Patient Population

“…These infectious diseases impair immune system, increase oxidative stresses induced by the viral proteins, and cause virus-associated organ damage including liver fibrosis, steatosis, or hepatocellular carcinoma [48]. [45] Postoperative bleeding risk of patients continuing their anticoagulation therapy (antiaggregant, vit-K inhibitors, vitamin-K inhibitor withdrawal bridged with heparin, direct oral anticoagulants) and undergoing implant surgery and advanced bone grafting procedures 564 patients…”

A gyógyszer indukálta vérzékeny betegek fogorvosi, szájsebészeti ellátása: a 2015-ös hazai szakmai ajánlás alkalmazása és értékelése

“…K-vitamin-antagonista (VKA) kezelésben ré-szesülő (például acenokumarol, phenokumarol), 3. az úgynevezett új típusú orális antikoagulánsokat szedő (az angol NOAC, novel anticoagulants szóból) betegek [2][3][4][5]. Ezen terápiák bármelyikében részesülő betegeknél a vérzéssel járó fogorvosi/szájsebészeti beavatkozások elvégzésére sokáig nem volt egységes hazai ajánlás.…”